ClinicalTrials.gov recorded primary completion on 17 March 2026 for a completed Phase 3 study comparing weekly GLP-1 receptor agonists in obese diabetic and obese non-diabetic participants. The trial enrolled 159 participants and listed dulaglutide, semaglutide, and tirzepatide among its interventions.
Background
The study evaluated different weekly GLP-1 receptor agonists in two listed populations: obese diabetics and obese non-diabetic participants. Dulaglutide was included at two listed strengths, 1.5 mg/ml and 0.75 mg for subcutaneous injection. Semaglutide was listed at 2 mg/1.5 ml in a prefilled pen-injector formulation and at 1.0 mg. Tirzepatide was described as being administered as part of routine clinical care for obesity management, with dosing and treatment duration determined by the treating physician.
The registry summary stated that the study examined different effects of dulaglutide, semaglutide, and tirzepatide among diabetic and non-diabetic participants. It referred to weight reduction and effects on metabolic processes, including insulin sensitivity, lipid profile, and NASH, but the supplied record did not provide results for those areas.
Trial design
This Phase 3 randomized controlled study was identified as NCT07820111 and had an overall status of completed. It enrolled 159 participants with the listed conditions “Obese Diabetics” and “Obese Non Diabetic.” The trial’s brief title described a comparative study of different weekly GLP-1 receptor agonists among diabetic and non-diabetic patients.
The listed interventions were dulaglutide 1.5 mg/ml, dulaglutide 0.75 mg by subcutaneous injection, semaglutide 2 mg/1.5 ml in a prefilled pen-injector, semaglutide 1.0 mg, and tirzepatide administered according to routine clinical care. The supplied record did not identify a primary endpoint, comparator-arm assignments, treatment duration, or outcome measurements.
What this means
The completed study provides a registry record of a randomized Phase 3 comparison involving 159 participants across obese diabetic and non-diabetic populations. However, the supplied data contain no primary-outcome results, key measurements, statistical analyses, confidence intervals, or adverse-event summary. The record therefore does not establish whether dulaglutide performed better, worse, or similarly to semaglutide or tirzepatide.
The available information supports describing the event as trial primary completion rather than a positive or negative efficacy finding. Any conclusions about weight reduction, insulin sensitivity, lipid profile, NASH, safety, or differences between the listed drugs require results that were not included in the supplied record.
Source
Source: ClinicalTrials.gov, trial registry record for the completed Phase 3 study “Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial,” with primary completion recorded on 17 March 2026. Available at clinicaltrials.gov/study/NCT07820111.